二、说明会召开的时间、地点 1、召开时间：2023 年 5 月 19 日（星期五）上午 09:00-10:00 证券代码：688767 证券简称：博拓生物 公告编号：2023-014 杭州博拓生物科技股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要提示： 上海证券交易所上证路演中心上海证券交易所上证路演中心 投资者可于 2023 年 5 月 18 日（星期四）16:00 前登录上证路演中心网站首 页点击"提问预征集"栏目或通过公司邮箱 ir.secretary@biotests.com.cn 进 行提问，公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 杭州博拓生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2022 年年度报 告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况， 公司计划于 2023 年 5 月 19 日上午 09:0 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 500 million yuan, representing a growth of 25% year-over-year[1]. - The company's operating revenue for the first half of 2022 was ¥1,523,920,126.55, representing a year-on-year increase of 31.62%[23]. - The net profit attributable to shareholders for the same period was ¥744,966,357.17, reflecting a growth of 30.99% compared to the previous year[23]. - The net cash flow from operating activities was ¥824,342,271.33, an increase of 11.73% year-on-year[23]. - The company's total assets reached ¥2,974,924,288.08, up 22.35% from the end of the previous year[23]. - The gross margin for the first half of 2022 was reported at 60%, an improvement from 55% in the same period last year[1]. - Operating profit reached CNY 877.10 million, an increase of 32.81% compared to the same period last year[77]. - The company reported a total revenue of RMB 297.58 million for the first half of 2022, with a net profit of RMB 115.66 million, representing a significant increase compared to the previous year[65]. Market Expansion and Strategy - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 30% based on new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share by the end of 2023[1]. - A strategic acquisition of a local biotech firm was announced, which is expected to enhance the company's product portfolio and increase operational efficiency[1]. - The company is strategically expanding its market presence in Asia, the Middle East, Europe, Africa, North America, and Latin America, enhancing its global footprint[41]. - The company has established a dual marketing system for domestic and international sales, focusing on direct sales and distribution channels to enhance market reach[41]. Research and Development - Research and development efforts focused on two new diagnostic products, expected to be launched by Q4 2022, which are anticipated to enhance market competitiveness[1]. - The board has approved a plan to reinvest 30% of profits into R&D to foster innovation and maintain competitive advantage[1]. - The R&D investment as a percentage of operating revenue increased to 4.55%, up 2.21 percentage points from the previous year[24]. - Total R&D investment reached 69.31 million yuan, a significant increase of 155.72% year-over-year[55]. - The company is focusing on the development of new technologies and products, including rapid testing kits for COVID-19 and other infectious diseases[39]. - The company is actively involved in the development of various diagnostic reagents, including those for infectious diseases and tumor markers, enhancing its product portfolio[38]. - The company has developed various drug abuse detection products, including tests for multiple drugs and specific substances like fentanyl and methamphetamine[33]. Product Development and Innovation - The company focuses on the POCT (Point-of-Care Testing) field, developing and selling diagnostic reagents, and is a leading enterprise in China's POCT industry[31]. - The main products include rapid diagnostic reagents for infectious diseases, drug abuse detection, tumor markers, myocardial markers, and reproductive health, covering hundreds of products[32]. - The company is accelerating the development of molecular diagnostic technology platforms, chemiluminescence technology platforms, microfluidic technology, and animal disease detection services[32]. - The company is expanding its molecular diagnostic product series based on RT-PCR and is enhancing its automated chemiluminescence detection platform[32]. - The company is committed to continuous product innovation and expanding its reagent list in the chemiluminescence field[32]. Risks and Challenges - The company has identified potential risks related to regulatory changes in the healthcare sector, which could impact future operations[1]. - The company faces risks related to new product development, including potential delays and registration challenges that could hinder market competitiveness[83]. - The company reported a high proportion of overseas sales, making it vulnerable to international political and economic fluctuations that could adversely affect performance[88]. - The global economic downturn poses a risk to the demand for non-COVID diagnostic products, potentially leading to significant revenue declines[95]. - Ongoing US-China trade tensions could hinder the company's business expansion in the US market, negatively impacting overall performance[96]. Environmental and Social Responsibility - The company actively complies with national environmental protection laws and regulations, ensuring minimal environmental impact from its operations[122]. - The company has implemented measures to improve water resource usage and reduce environmental impact, including the use of energy-saving and water-saving devices[122]. - The company promotes a green office environment by encouraging practices like double-sided printing and reducing paper usage[127]. - The company has established a dedicated hazardous waste warehouse and manages hazardous waste in compliance with local regulations[124]. - The company emphasizes the importance of environmental management by establishing an EHS management system and appointing dedicated personnel for oversight[124]. Shareholder Commitments and Governance - The company reported a commitment to not transfer or delegate management of pre-IPO shares for 36 months post-IPO, ensuring stability in shareholding[135]. - The actual controllers and major shareholders have committed to not proposing share buybacks during the lock-up period, reinforcing shareholder confidence[139]. - The company has established measures to ensure that its directors and senior management do not misuse their positions or harm the company's interests[174]. - The company will ensure that any violations of commitments regarding shareholding intentions or reductions will result in the proceeds being surrendered to the company[180]. - The company has committed to a long-term holding strategy for shares by major shareholders, with a focus on maintaining stock price stability[151].

Financial Performance - The company's operating revenue for 2021 was CNY 1,818,075,902.95, representing a 110.09% increase compared to CNY 865,371,453.85 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 833,590,633.07, a 91.57% increase from CNY 435,146,719.99 in 2020[23]. - The net cash flow from operating activities for 2021 was CNY 908,123,247.63, up 103.58% from CNY 446,065,971.55 in 2020[23]. - The total assets at the end of 2021 reached CNY 2,431,508,922.58, a 283.57% increase from CNY 633,915,895.72 at the end of 2020[23]. - The net assets attributable to shareholders increased to CNY 2,107,098,138.47, a 374.42% rise from CNY 444,137,738.24 at the end of 2020[23]. - Basic earnings per share for 2021 were CNY 9.62, a 76.84% increase from CNY 5.44 in 2020[24]. - The net profit after deducting non-recurring gains and losses was CNY 825,500,564.78, reflecting a 92.13% increase from CNY 429,655,450.62 in 2020[23]. - The company's revenue increased by 110.09% from 2020 to 2021, reaching ¥1.818 billion, up from ¥865 million[57]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 30.00 CNY per 10 shares, totaling 320,000,001.00 CNY, which represents 38.39% of the net profit attributable to shareholders for 2021[5]. - The company has not proposed any capital reserve transfer to increase share capital or stock dividends for the current period[5]. - The company has a mixed compensation strategy, ensuring that cash distributions are at least 10% of the distributable profits for the year, provided there are no major investment plans[198]. - The cash dividend policy stipulates that for mature companies without major capital expenditures, cash dividends should constitute at least 80% of the profit distribution[199]. Research and Development - The research and development expenditure as a percentage of operating revenue was 3.41% in 2021, down 1.37 percentage points from 4.78% in 2020[24]. - R&D expenses for 2021 amounted to 61.92 million yuan, representing a 49.85% increase year-over-year[38]. - The company has a strong focus on R&D, with a total of 261 patent applications filed, of which 193 have been authorized[67]. - The company has developed multiple new technologies, including time-resolved immunofluorescence technology and multiplex detection technology, to enhance diagnostic capabilities[64]. - The company invested significantly in R&D for new products and technologies to meet diverse market demands[36]. - The company has obtained 33 new patents during the reporting period, including 27 domestic and 6 international patents[38]. Market Expansion and Sales Strategy - The company expanded its product lines in drug abuse testing and infectious disease testing, responding to the increased demand for COVID-19 testing[36]. - The company has entered new international markets including Russia, Australia, Switzerland, and Mexico, enhancing its global sales channels[39]. - The company has established a dual marketing system for domestic and international sales, with five regional sales managers responsible for different geographic areas in China[47]. - The company aims to enhance its core competitiveness by increasing R&D investment in molecular diagnostics and animal testing technology platforms[152]. - The company plans to accelerate the R&D and registration of COVID-19 products to meet the rising demand for home testing kits in major markets[156]. Risk Management - The company has identified significant risk factors that may adversely affect its operations, which are detailed in the management discussion section[4]. - The company emphasizes the importance of caution regarding forward-looking statements and investment risks[7]. - The company has a comprehensive risk management strategy in place to address potential adverse impacts on its business[4]. - The company faces risks related to new product development, including potential delays and registration challenges that could hinder market competitiveness and profitability[98]. - The company has a high customer concentration risk, with the top five customers accounting for 83.62% of sales, and reliance on the largest customer at 60.84% of total revenue, posing a threat to future orders[101]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[6]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company does not have any non-operating fund occupation by controlling shareholders or related parties[8]. - The company received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. Employee and Management Information - The total number of employees in the parent company is 553, while the main subsidiaries have 69 employees, resulting in a total of 622 employees[190]. - The company has 23 retired employees for whom it bears expenses[190]. - The company emphasizes employee training, with key programs including a 12-month training for new graduates and a management training camp for middle-level managers[194]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to RMB 1,809.63 million[179]. - The actual remuneration for core technical personnel at the end of the reporting period was RMB 631.82 million[179]. Financial Position and Capital Management - Cash and cash equivalents increased to ¥1,367,736,419.05, representing a 423.69% increase compared to the previous period[138]. - Accounts receivable rose to ¥146,907,009.69, a 52.61% increase, attributed to significant business growth[138]. - Inventory increased to ¥141,704,232.16, reflecting a 53.38% growth due to expanded purchasing scale[138]. - The company reported a significant increase in accounts payable, which rose by 102.29% to ¥224,324,511.70, reflecting increased purchasing scale[139]. - The company’s deferred income tax assets increased by 97.69% to ¥3,007,309.76, due to growth in bad debt provisions and inventory depreciation[139].

Financial Performance - The company's operating revenue for Q1 2022 reached ¥1,017,267,845.08, representing a year-on-year increase of 106.83%[5] - Net profit attributable to shareholders was ¥492,528,719.71, reflecting a growth of 111.25% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥484,445,824.96, an increase of 107.92% year-on-year[10] - Basic earnings per share were ¥4.62, up by 58.68% from the previous year[10] - Operating profit for Q1 2022 was ¥582,914,745.56, up 113.0% from ¥273,429,534.36 in the same period last year[23] - Net profit for Q1 2022 was ¥493,587,345.24, representing a 112.5% increase from ¥232,739,290.16 in Q1 2021[23] - Total operating costs for Q1 2022 were ¥445,116,101.97, which is 106.7% higher than ¥215,002,694.83 in Q1 2021[22] - The total comprehensive income for Q1 2022 was ¥493,573,794.84, up from ¥232,646,007.62 in Q1 2021[24] Cash Flow and Assets - The net cash flow from operating activities was ¥696,516,794.88, showing a significant increase of 131.89%[10] - Cash flow from operating activities for Q1 2022 was ¥696,516,794.88, an increase of 132.9% from ¥300,369,138.70 in Q1 2021[26] - Cash and cash equivalents at the end of Q1 2022 totaled ¥2,017,795,409.79, up from ¥523,392,039.85 at the end of Q1 2021[26] - The company's cash and cash equivalents reached ¥2,017,919,909.79, up from ¥1,367,736,419.05, indicating a growth of about 47.5%[18] - Total assets at the end of the reporting period amounted to ¥3,181,979,046.82, a 30.86% increase from the end of the previous year[6] - As of March 31, 2022, the total assets of the company amounted to ¥3,181,979,046.82, an increase from ¥2,431,508,922.58 at the end of December 2021, representing a growth of approximately 31%[19] - The company reported a total current assets of ¥2,756,825,709.92, up from ¥2,032,709,544.64, which is an increase of approximately 35.5%[19] Liabilities and Equity - Total current liabilities increased to ¥575,044,013.77 from ¥317,560,242.74, reflecting a rise of approximately 81%[20] - The company’s total liabilities reached ¥580,255,822.87, up from ¥323,359,493.47, indicating an increase of about 79.5%[20] - The company's total equity attributable to shareholders rose to ¥2,599,614,662.82, compared to ¥2,107,098,138.47, marking an increase of around 23.3%[20] - The company’s retained earnings increased to ¥1,623,986,917.39 from ¥1,131,458,197.68, reflecting a growth of approximately 43.4%[20] Research and Development - Research and development expenses totaled ¥19,586,991.87, which is 60.31% higher than the same period last year[10] - Research and development expenses for Q1 2022 amounted to ¥19,586,991.87, an increase of 60.5% from ¥12,218,054.31 in Q1 2021[22] - The proportion of R&D expenses to operating revenue was 1.93%, a decrease of 0.55 percentage points[6] Accounting and Reporting - The company announced the implementation of new accounting standards starting from Q1 2022[27] - The financial statements related to the first execution of the new accounting standards were adjusted at the beginning of the year[27] - The board of directors of Hangzhou Botao Biotechnology Co., Ltd. issued the report on April 26, 2022[27] - The report indicates that it is not applicable to the new accounting standards for the first quarter of 2022[27] - The document does not provide specific financial performance metrics or user data for Q1 2022[27] - There are no future outlooks or performance guidance mentioned in the report[27] - The report lacks information on new product or technology development[27] - There are no details regarding market expansion or mergers and acquisitions[27] - The document does not outline any new strategies[27] - The report consists of 15 pages, indicating a comprehensive overview of the company's financial status[27]

Financial Performance - The company's revenue for Q3 2021 reached CNY 345,463,545.50, representing a year-over-year increase of 129.79%[5] - Net profit attributable to shareholders for Q3 2021 was CNY 150,379,747.43, reflecting a significant increase of 179.93% compared to the same period last year[5] - The basic earnings per share for Q3 2021 was CNY 1.88, which is an increase of 180.60% year-over-year[6] - The company reported a net profit attributable to shareholders of CNY 719,110,208.38 for the year-to-date period, which is an increase of 101.88% compared to the same period last year[5] - The diluted earnings per share for the year-to-date period was CNY 8.99, reflecting a growth of 102.02% year-over-year[10] - Net profit for the first three quarters of 2021 was ¥719,656,667.86, up from ¥356,492,232.96 in 2020, reflecting a growth of approximately 102%[22] - Basic earnings per share for the first three quarters of 2021 were ¥8.99, compared to ¥4.45 in the same period of 2020, marking an increase of about 102%[23] Assets and Liabilities - Total assets as of the end of Q3 2021 amounted to CNY 2,315,898,293.32, showing a growth of 265.33% compared to the previous year[10] - Total current assets rose to ¥1,979,624,065.65, up from ¥467,986,371.62 in the previous year[16] - Non-current assets increased to ¥336,274,227.67 from ¥165,929,524.10 year-over-year[17] - Total liabilities as of the end of the reporting period amounted to ¥323,919,751.75, compared to ¥190,892,214.33 in the previous year, showing an increase of about 70%[18] - The total liabilities increased from ¥190,892,214.33 to ¥200,154,100.25, indicating a rise in the company's obligations[31] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 795,973,298.39, an increase of 124.54%[6] - The net cash flow from operating activities for Q3 2021 was ¥795,973,298.39, an increase from ¥354,486,898.74 in Q3 2020, representing a growth of approximately 124.8%[26] - Cash generated from operating activities in the first three quarters of 2021 was ¥1,474,750,036.81, compared to ¥651,883,260.39 in 2020, representing an increase of approximately 126%[25] - The net cash flow from financing activities after outflows was ¥829,810,921.57, a turnaround from a negative cash flow of -¥128,308,228.05 in the previous year[27] - The company received tax refunds amounting to ¥56,373,677.54, compared to ¥17,782,412.91 in the previous year, showing an increase of approximately 216.5%[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,484[13] - The largest shareholder, Hangzhou Tuokang Investment Co., Ltd., holds 24,896,000 shares, accounting for 23.34% of total shares[13] - The company has no pledged, marked, or frozen shares among its top shareholders[13] Research and Development - Research and development expenses for Q3 2021 totaled CNY 11,375,236.55, accounting for 3.29% of revenue, a decrease of 2.04 percentage points from the previous year[6] - The company has invested ¥38,479,049.32 in research and development expenses during the first three quarters of 2021, compared to ¥26,395,079.08 in the same period of 2020, reflecting an increase of approximately 46%[21] Operational Highlights - The company experienced a significant increase in sales revenue and profit scale due to the heightened demand for COVID-19 testing products[9] - Total operating revenue for the first three quarters of 2021 reached ¥1,503,248,673.80, a significant increase from ¥643,793,253.72 in the same period of 2020, representing a growth of approximately 133%[21] - Total operating costs for the first three quarters of 2021 were ¥661,835,705.18, compared to ¥221,032,229.89 in 2020, indicating an increase of about 199%[21] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of -¥71,027.99 for the first three quarters of 2021, compared to ¥205,116.11 in 2020[22] - The company has not disclosed any significant new strategies or product developments during the reporting period[15]